Research Article| Volume 25, ISSUE 6, P1451-1457, June 2016

Phase II Trial of Intravenous Low-Dose Granulocyte Colony-Stimulating Factor in Acute Ischemic Stroke


      Granulocyte colony-stimulating factor (G-CSF) has shown neuroprotective and neurogenerative activities in experimental studies, and our previous phase I clinical study suggested the safety and potential efficacy of low-dose G-CSF in acute ischemic stroke patients. The present phase II trial is aimed to evaluate the effect of G-CSF administration on neurological function and infarct volume, compared with a placebo group.


      Forty-nine acute ischemic stroke patients (29 males, 20 females; 71 ± 10 years) within 24 hours after onset were recruited. Eligible patients were randomized 2:2:1 to receive G-CSF 150 µg/body/day, G-CSF 300 µg/body/day, and placebo, respectively. We evaluated clinical outcome in terms of the National Institutes of Health Stroke Scale, the modified Rankin Scale, and the Barthel Index at 90 days after onset, together with changes in infarct volume on magnetic resonance imaging.


      We found no serious adverse event, including change in leukocyte levels, which remained below 31,000/µL, at 150 and 300 µg G-CSF/body/day. Clinical outcome scores did not show any significant difference among the 3 groups. Chronological changes in infarct volume also showed no significant difference.


      G-CSF was well-tolerated at 150 and 300 µg/body/day in patients with acute ischemic stroke. However, administration of G-CSF at both 150 and 300 µg/body/day neither contributed to functional recovery nor reduced infarct volume at 3 months after onset, compared with the control group. The apparent lack of effectiveness may have been due to the small sample size. A trial of combination therapy with recombinant tissue plasminogen activator and G-CSF is planned.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Edaravone Acute Infarction Group
        Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.
        Cerebrovasc Dis. 2003; 15: 222-229
        • Noisa P.
        • Raivio T.
        • Cui W.
        Neural progenitor cell derived from human embryonic stem cells as an origin of dopaminergic neurons.
        Stem Cells Int. 2015; 2015: 647437
        • Torrent R.
        • De Angelis Rigotti F.
        • Dell'Era P.
        • et al.
        Using iPS cells toward the understanding of Parkinson's disease.
        J Clin Med. 2015; 4: 548-566
        • Cavallaro A.M.
        • Lilleby K.
        • Majolino I.
        • et al.
        Three to six year follow-up of normal donors who received recombinant human granulocyte colony stimulating factor.
        Bone Marrow Transplant. 2000; 25: 85-89
        • Minnerup J.
        • Sevimli S.
        • Schabitz W.R.
        Granulocyte-colony stimulating factor for stroke treatment: mechanisms of action and efficacy in preclinical studies.
        Exp Transl Stroke Med. 2009; 1: 2
        • Solaroglu I.
        • Jadhav V.
        • Zhang J.H.
        Neuroprotective effect of granulocyte-colony stimulating factor.
        Front Biosci. 2007; 12: 12-24
        • Kawada H.
        • Takizawa S.
        • Takanashi T.
        • et al.
        Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells.
        Circulation. 2006; 113: 701-710
        • Morita Y.
        • Takizawa S.
        • Kamiguchi H.
        • et al.
        Administration of hematopoietic cytokines increases the expression of anti-inflammatory cytokine (IL-10) mRNA in the subacute phase after stroke.
        Neurosci Res. 2007; 58: 356-360
        • Gibson C.L.
        • Bath P.M.
        • Murphy S.P.
        G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice.
        J Cereb Blood Flow Metab. 2005; 25: 431-439
        • Komine-Kobayashi M.
        • Zhang N.
        • Liu M.
        • et al.
        Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice.
        J Cereb Blood Flow Metab. 2006; 26: 402-413
        • Schabitz W.R.
        • Kollmar R.
        • Schwaninger M.
        • et al.
        Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia.
        Stroke. 2003; 34: 745-751
        • Abe K.
        • Yamashita T.
        • Takizawa S.
        • et al.
        Stem cell therapy for cerebral ischemia—from basic science to clinical applications.
        J Cereb Blood Flow Metab. 2012; 32: 1317-1331
        • Shyu W.C.
        • Lin S.Z.
        • Lee C.C.
        • et al.
        Granulocyte colony- stimulating factor for acute ischemic stroke: a randomized controlled trial.
        CMAJ. 2006; 174: 927-933
        • Sprigg N.
        • Bath P.M.
        • Zhao L.
        • et al.
        Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of Recovery Enhancement after Stroke (STEMS) pilot randomized, controlled trial.
        Stroke. 2006; 37: 2979-2983
        • Prasad K.
        • Kumar A.
        • Sahu J.K.
        • et al.
        Mobilization of stem cells using G-CSF for acute ischemic stroke: a randomized controlled, pilot study.
        Stroke Res Treat. 2011; 2011: 283473
        • England T.J.
        • Abaei M.
        • Auer D.P.
        • et al.
        Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the Stem Cell Trial of Recovery Enhancement After Stroke 2 Randomized Controlled Trial.
        Stroke. 2012; 43: 405-411
        • Ringestein E.B.
        • Thijs V.
        • Norrving B.
        • et al.
        Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial.
        Stroke. 2013; 44: 2681-2687
        • Moriya Y.
        • Mizuma A.
        • Uesugi T.
        • et al.
        Phase I study of intravenous low-dose granulocyte colony-stimulating factor in acute and subacute ischemic stroke.
        J Stroke Cerebrovasc Dis. 2013; 22: 1088-1097
        • Adams Jr, H.P.
        • Bendixen B.H.
        • Kappelle L.J.
        • et al.
        Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
        Stroke. 1993; 24: 35-41
        • Hadidi S.
        • Glenney G.W.
        • Welch T.J.
        • et al.
        Spleen size predicts resistance of rainbow trout to Flavobacterium psychrophilum challenge.
        J Immunol. 2008; 180: 4156-4165
        • Schabitz W.R.
        • Laage R.
        • Vogt G.
        • et al.
        AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke.
        Stroke. 2010; 41: 2545-2551
        • Duelsner A.
        • Gatzke N.
        • Glaser J.
        • et al.
        Granulocyte colony-stimulating factor improves cerebrovascular reserve capacity by enhancing collateral growth in the circle of Willis.
        Cerebrovasc Dis. 2012; 33: 419-429
        • dela Pena I.C.
        • Yoo A.
        • Tajiri N.
        • et al.
        Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.
        J Cereb Blood Flow Metab. 2015; 35: 338-346